89BIO (ETNB)
(Delayed Data from NSDQ)
$9.69 USD
+0.35 (3.75%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $9.68 -0.01 (-0.10%) 5:28 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, 89BIO has a market cap of $1.36B, which represents its share price of $9.34 multiplied by its outstanding shares number of 145.98M. As a small-cap company, ETNB's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
ETNB 9.69 +0.35(3.75%)
Will ETNB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ETNB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ETNB
Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason
ETNB: What are Zacks experts saying now?
Zacks Private Portfolio Services
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study
VRTX Secures Nod for Expanded Use of CF Drug Kaftrio in Europe
FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug
Other News for ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ETNB Stock News
Altimmune: Potential Tough Road Ahead Amid Fierce Competition (Rating Downgrade)
89bio Inc (ETNB) Announces Inducement Grants for New Employees | ETNB stock news
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ETNB Stock News
Empery Asset Management, LP Reduces Stake in Volcon Inc